Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus [Yahoo! Finance]
Tenaya Therapeutics, Inc. (TNYA)
Company Research
Source: Yahoo! Finance
12, 2026, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported Q4 EPS of (12c), in line with the (12c) consensus estimate. CEO Faraz Ali said the company is entering the year with “momentum” following clinical progress in 2025, highlighting encouraging data from its lead gene therapy programs. Ali noted that Tenaya expects to provide additional updates in the first half of 2026, including longer-term data from the MyPEAK-1 trial of TN-201 and new data from the RIDGE-1 trial of TN-401, while also working toward regulatory alignment on pivotal trial plans. On March 9, 2026, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) presented preclinical data for TN-301, its selective HDAC6 inhibitor, at the Muscular Dystrophy Association's Clinical & Scientific Conference 2026. In models of Duchenne muscular dystrophy, TN-301 improved muscle performance and addressed markers of muscle injury, including reductions in creatine kinase activity. The compound also showed improvements in cardiac-related cellular
Show less
Read more
Impact Snapshot
Event Time:
TNYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNYA alerts
High impacting Tenaya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNYA
News
- Tenaya Therapeutics (TNYA) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TNYA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hoMarketBeat
- Tenaya Therapeutics (TNYA) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- Tenaya Therapeutics (TNYA) had its "outperform" rating reaffirmed by William Blair.MarketBeat
- Tenaya Therapeutics (TNYA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $8.00 price target on the stock.MarketBeat
- Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
TNYA
Earnings
- 3/11/26 - Beat
TNYA
Sec Filings
- 3/11/26 - Form 10-K
- 3/11/26 - Form 8-K
- 3/5/26 - Form 8-K
- TNYA's page on the SEC website